I’ve been keeping an eye on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe ZYNE has a lot to offer. Basically, it is a company with impressive financial health as well as a buoyant future outlook. Below is a brief commentary on these key aspects. If you’re interested in understanding beyond my high-level commentary, take a look at the report on Zynerba Pharmaceuticals here.
Flawless balance sheet with high growth potential
ZYNE’s strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This indicates that ZYNE has sufficient cash flows and proper cash management in place, which is a key determinant of the company’s health. ZYNE currently has no debt on its balance sheet. It has only utilized funding from its equity capital to run the business, which is typically normal for a small-cap company. ZYNE has plenty of financial flexibility, without debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future.
For Zynerba Pharmaceuticals, I’ve put together three pertinent aspects you should further research:
- Historical Performance: What has ZYNE’s returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Valuation: What is ZYNE worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether ZYNE is currently mispriced by the market.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of ZYNE? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at email@example.com.